Cicaderm

Quick links to important sections

Cicaderm

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cicaderm

Quick Facts

Property Description
Active ingredient Zinc Oxide
Form Ointment, Cream, or Paste
Pharmacological class Topical Protectant / Dermatological Agent
Common use Creating a physical barrier on the skin
Origin Inorganic Compound (Mineral-derived)

What Type of Medicine is Cicaderm and Its Pharmacological Class?

Cicaderm is a topical pharmaceutical preparation intended strictly for external use, classifying it as a Dermatological Agent. Its primary designation is a Topical Protectant, a classification assigned to products designed to physically shield the skin from irritants. This formulation, containing Zinc Oxide, is clinically recognized for its role in creating optimal conditions for skin repair, particularly in sensitive patient groups. This designation confirms that the preparation's function is non-systemic, meaning its benefits are exerted solely on the surface without being intended for absorption into the body.

The Composition of Cicaderm: Zinc Oxide and Formulation

The core active ingredient in Cicaderm is Zinc Oxide, an inorganic compound widely accepted in the medical community for its gentle profile. Zinc Oxide is typically incorporated into a dense dosage form such as an ointment, topical cream, or topical paste. The vehicle is often a fatty or hydrophobic paste base, which is necessary for creating the physical barrier required for its function. The formulation's primary differentiation lies in the stable suspension of the mineral-derived Zinc Oxide within the base, ensuring consistent coverage when applied to protect areas prone to persistent moisture or friction.

What is the General Purpose of Cicaderm?

The general purpose of Cicaderm is to provide a soothing and calming effect by establishing a durable, physical protective barrier over irritated skin. The mechanism leverages the inherent properties of Zinc Oxide, which include mild astringent properties to help contract superficial tissues and manage surface moisture, supporting the body’s intrinsic cicatrizant (wound-healing) process. By continuously shielding the skin from external factors and friction, the preparation effectively mitigates localized discomfort, which is a typical use scenario when managing minor superficial skin irritations.

Regulatory References

  1. DailyMed Label for Zinc Oxide Ointment

What side effects are possible with Cicaderm?

Possible Side Effects and Safety Information

The safety profile of Cicaderm, which contains Zinc Oxide and is classified as a Topical Protectant, is characterized by reactions that are primarily confined to the site of application. Since it is intended for external use and has negligible systemic absorption, the officially documented safety concerns revolve around local tolerance.


Documented Adverse Reactions

Adverse reactions associated with this type of topical preparation are generally classified by regulatory authorities as Frequency Not Known, meaning they cannot be reliably estimated from available data. The effects are contained within the Skin and Subcutaneous Tissue Disorders system-organ class.

  • Local Irritation: Reactions at the site of application, such as mild local redness, stinging, or burning, are the most commonly observed local adverse events.
  • Skin Sensitization: The potential for a localized allergic reaction, appearing as a rash or hives, is also documented in regulatory labeling.

Serious Adverse Reactions and Safety Constraints

Regulatory documents acknowledge the extremely rare potential for severe systemic hypersensitivity reactions, including anaphylaxis or angioedema, which is a general safety consideration for any medicinal product. The most critical official safety constraints are:

  • Contraindication: The medicine is formally contraindicated in individuals with a known hypersensitivity (allergy) to Zinc Oxide or any other component of the formulation.
  • External Use Only: Cicaderm is strictly for external application, and contact with the eyes must be avoided.

No specific safety restrictions or dosage adjustments are typically listed in official labeling for populations such as older adults, or those with renal or hepatic impairment, consistent with the product's non-systemic use.

Overdose and Emergency Response

Cicaderm Overdose and when to seek help

The official regulatory profile for Cicaderm, a topical protectant, is defined by the risk of accidental oral ingestion of the preparation, as it is intended for external, non-systemic use.

Documented Overdose Manifestations

Systemic presentations following accidental swallowing include acute gastrointestinal disturbances and constitutional symptoms. Regulatory documents list manifestations such as nausea, vomiting, diarrhea, and stomach pain, along with fever and chills. In severe cases of systemic exposure, life-threatening outcomes requiring immediate emergency intervention may occur, specifically trouble breathing or loss of consciousness.

Mandated Emergency Actions

Regulators mandate specific actions for accidental overdose. An individual must contact a Poison Control Center right away and seek medical help. Calling 911 (emergency services) is the required instruction if severe symptoms like passing out or trouble breathing are observed. For localized topical issues, official guidance states to discontinue use and consult a health care provider if the condition worsens or persists.

Supportive Management and Antidote Status

Management is consistently defined as symptomatic and supportive treatment, including the use of procedural measures such as activated charcoal and intravenous fluids. No specific antidote is known for the effects of this preparation in overdose. Monitoring of vital signs and diagnostic testing are documented requirements in the overdose setting to support treatment.

Therapeutic Uses of Cicaderm

Cicaderm is commonly used as a topical skin protectant across several dermatological contexts. It is applied in situations involving dermatitis caused by persistent moisture and rubbing, such as Diaper Dermatitis and chafing, and for soothing acute localized discomfort from minor abrasions, windburn, or superficial first-degree burns.

The agent is relevant for managing symptoms linked to organ-specific functional stress (skin barrier compromise), including severely chapped or cracked skin. It may also assist with managing surface oozing or weeping caused by irritants. The use of this preparation contributes to the maintenance of a protective barrier, which supports the body during episodes of inflammation.

“This topical agent contributes to easing the overall symptom load during symptomatic periods.”

This supportive therapeutic approach helps patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Symptom Management

Symptom Focus Therapeutic Benefit
Burning and Soreness Contributes to improved day-to-day comfort during symptomatic periods.
Moisture/Weeping Is applied in addressing symptoms related to moisture and surface weeping.
Friction/Rubbing Plays a role in managing symptoms related to inflammatory or irritative states by providing symptomatic support.

Regulatory References

  1. DailyMed overview from the NIH/FDA

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults and Children are eligible for general use as a topical protectant.

Populations for whom use is contraindicated: Patients with a known hypersensitivity or allergy to Zinc Oxide or any other ingredient in the specific formulation.

Age-related eligibility rules:

  • Use is established for the general pediatric population.
  • Official documents state that no information is available on the relationship of age to the effects in geriatric patients.

Condition-specific eligibility rules:

  • Use is prohibited for fungal infections and on large surface wounds or burns.
  • The product must not be applied to exudative and/or superinfected lesions.

Pregnancy and lactation eligibility status (if explicitly documented): Regulatory documents indicate that it is not necessary to contraindicate use during pregnancy or lactation due to minimal systemic absorption.

Eligibility-related restrictions: Use should not occur without the advice of a healthcare provider if Infection of the skin or severe skin injury is present at the place of application.

Connection to the overall eligibility profile

Official regulatory documents define eligibility by establishing an absolute exclusion based on component hypersensitivity. The profile outlines strict conditional limitations based on the severity and type of skin condition, such as prohibiting use on infected or severely broken skin. For vulnerable populations, data limitations are noted, indicating that effects are not established for the elderly.

What should I know about interactions with other medicines?

Cicaderm Interactions with other medicines and products

Official regulatory documents from authoritative bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) do not list specific drug-drug or drug-product interaction requirements for Cicaderm. Available data suggests the product is generally classified outside the scope of prescription drug regulation, typically as a cosmetic, dietary supplement, or non-prescription dermatological preparation, which explains the absence of a standardized, government-mandated interaction section in the regulatory sense.

In the context of regulated medicines, interaction documentation outlines which medicinal products or substances, such as CYP enzyme inhibitors or inducers, cannot be co-administered or require a dosage modification. As no such official drug labeling exists for Cicaderm, there are no pharmacokinetically or pharmacodynamically mediated interaction statements. There are no explicit regulatory restrictions for co-administration with other specified medicines, drug classes, or common over-the-counter products because its regulatory classification does not require the extensive drug interaction testing and labeling mandatory for new prescription drugs. Patients should consult a healthcare professional regarding any product combinations to ensure safety and effectiveness.

Mechanism of Action

Physical Barrier and Epidermal Stabilization

The primary mechanism of action is non-systemic, involving the immediate formation of an occlusive layer on the Stratum Corneum. This inert matrix of Zinc Oxide particles acts as a durable blockade, functionally isolating the underlying tissue from external irritants and friction. This physical action restricts the transfer of mechanical and chemical stimuli to deeper epidermal layers, resulting in the preservation of epidermal integrity and the reduction of stimulus-induced activation of local sensory fibers.

Local Biochemical Modulation and Pathway Support

The mechanism includes an active biochemical component driven by the release of Zinc ions ( Zn^2+) in the presence of moisture. These ions function as a crucial co-factor for numerous metalloproteinases and enzymes (e.g., Superoxide Dismutase) vital for tissue regeneration and antioxidant defense. By supporting keratinocyte proliferation and fibroblast activity, the mechanism engages the intrinsic cicatrization pathway to support cellular recovery. Furthermore, Zn^2+ modulates the local inflammatory cascade by suppressing the secretion of key pro-inflammatory cytokines (e.g., IL-1alpha), thereby helping to maintain homeostatic balance within the cellular environment.

Dosage and Administration Information

Official Administration Guidelines for Cicaderm

Cicaderm, a topical preparation containing Zinc Oxide, is used exclusively as a Topical Protectant. The official instructions for use emphasize maintaining a physical barrier on the skin's surface.

Administration Detail Standard Instruction
Route of Administration Topical (For external use only).
Approved Forms Ointment, Cream, or Paste.
Standard Dosing Apply liberally or a sufficient amount to completely cover the affected area, forming a protective layer.
Frequency As often as necessary to maintain the barrier, typically multiple times daily. For uses like diaper rash, application is required with each diaper change.

Procedural Use and Instructions

Proper use relies on strict adherence to preparatory steps before applying the product:

  1. The skin area must be cleansed gently and allowed to dry thoroughly prior to application.
  2. Apply the cream, paste, or ointment liberally to ensure the entire surface is covered.
  3. Reapply the preparation promptly if the barrier becomes soiled or wet, particularly for uses involving persistent moisture exposure.

Population-Specific Rules

Cicaderm is approved for use in adults and children, including infants (e.g., for diaper rash), applying the same core principle of liberal, as-needed application. No specific dose adjustment is required for the elderly or patients with organ impairment, consistent with its non-systemic use.

If a reapplication time is missed, the preparation should simply be applied at the next needed time, as there are no fixed dosing schedules.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cicaderm (Topical Zinc Oxide)

This summary provides an overview of the types of research conducted for topical Zinc Oxide (the active ingredient in Cicaderm), what the studies explored, and where research limitations exist. The findings described relate to patterns observed in specific study groups and do not provide individual medical predictions or advice.

Evidence for Use in Diaper Dermatitis and Incontinence-Related Skin Irritation

Research examined conditions characterized by inflammatory or irritative states like diaper dermatitis, used in research exploring how symptoms change over time. This evidence primarily included short-term Randomized Controlled Trials (RCTs) and systematic reviews, studying infants and neonates and older adults with incontinence-related skin issues. Studies monitored outcomes related to physical discomfort and changes in irritation severity scales.

Findings describe patterns observed in the studies over defined time intervals, often lasting less than one week. Reported outcomes were frequently gathered when the topical protectant was associated with the use of a structured, consistent skin care regimen. This suggests the specific contribution of the preparation may be difficult to isolate entirely from the effects of the accompanying standardized care regimen.

Research on Chronic Friction and Superficial Skin Irritations (Intertrigo)

Research explored short-term symptom changes related to chronic friction and moisture-induced dermatitis. The evidence base includes intermediate-term comparative trials and open-label studies on adult patients. Studies monitored patient-reported outcomes describing perceived discomfort (such as itching and burning) and changes in objective signs like redness.

However, the certainty remains low because many of these studies involved combination products (containing other ingredients alongside zinc oxide). This means the evidence for the role of zinc oxide alone is challenging to differentiate, and the sample sizes were modest in some of these trials.

What Research Gaps and Uncertainties Remain

The overall evidence consistency varies across studies, particularly for minor wounds where the certainty remains low due to reliance on experimental data. Follow-up durations were limited across most indications; therefore, long-term effects are not fully established. Comparative evidence remains limited in cases where the preparation was evaluated in a multi-component formulation. Finally, the evidence contributes to understanding symptom patterns, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Zinc oxide (topical application route) - Description, Dosing, and Storage
  2. Comparative Study between Talcum and Zinc Oxide Cream for the Prevention of Irritant Contact Diaper Dermatitis in Infants

Frequently Asked Questions (FAQ)

Common questions about Cicaderm (FAQ)


Q: Is Cicaderm safe to use long-term?

Regulatory documents instruct users to stop using the product and seek medical advice if symptoms persist for more than seven days or if they return shortly after clearing up. Official research has focused primarily on short-term studies, and long-term effects for this class of topical protectants are not fully established in official documents.


Q: How quickly does Cicaderm start to have an effect?

The primary function of Cicaderm is to immediately form a physical, protective layer on the surface of the skin. The occlusive barrier is formed immediately upon application to physically shield the treated area from irritants.


Q: Are the side effects of Cicaderm permanent?

The documented adverse reactions, such as burning or irritation, are typically mild and localized. Official labeling directs users to stop applying the product if the condition worsens or if symptoms persist for more than seven days. These instructions align with the expectation that localized reactions are generally temporary.


Q: Is the effect of Cicaderm supposed to last all day?

Official directions state that the product should be applied liberally as often as necessary to maintain a complete protective barrier over the area. The guidelines specify that reapplication is necessary when the barrier is no longer intact, such as when the treated area becomes soiled or wet.


Q: What happens if I use Cicaderm for longer than the recommended time?

Official regulatory guidelines instruct users to discontinue application if the skin condition worsens or if the symptoms have not resolved within seven days. The effects of using the product for extended periods are not fully established in the available research, which focuses primarily on short-term outcomes.


Q: Does Cicaderm contain any known allergens like gluten or common preservatives?

Official labeling for this product class lists ingredients such as mineral oil and petrolatum as inactive components. While many topical products are formulated to avoid common allergens, reviewing the detailed list of inactive ingredients on the product’s package is necessary for individuals with specific allergies.


Q: How does the FDA classify Cicaderm?

According to the official product classification, Cicaderm is designated by the FDA as an Over-the-Counter (OTC) Drug. It falls under the Skin Protectant category of the official OTC Monograph system.


Q: Is the research evidence for Cicaderm considered strong by medical bodies?

Studies and official literature indicate that the evidence base for topical Zinc Oxide primarily comes from short-term trials. The available research indicates that the overall evidence consistency varies across studies, and the contribution of the product may be challenging to isolate from a standardized care regimen.


Q: What is the physical appearance of the Cicaderm product (color, texture)?

In its approved forms as an ointment, cream, or paste, Cicaderm typically appears white or opaque. The formulation is designed to be thick and dense to ensure the formation of the durable, visible barrier composed of the active ingredient, Zinc Oxide.


Q: Why is Cicaderm only available in certain application forms (e.g., cream, gel)?

The product is regulated and approved for forms like ointment, cream, and paste. These forms are typically required to create the specific hydrophobic, occlusive barrier for which the product is intended.


Q: Is Cicaderm considered a prescription medicine or over-the-counter?

Official product information indicates that Cicaderm is classified as an Over-the-Counter (OTC) medicine. This designation means it is regulated for direct sale to the public without a prescription.


Q: Are there any common interactions with food or specific drinks?

Official regulatory documents do not list any warnings regarding interactions with food or specific drinks. This is consistent with the product’s non-systemic classification, meaning it is not significantly absorbed into the body and does not affect systemic circulation.


Q: Can I use Cicaderm if I am also taking vitamins or supplements?

Because the product is non-systemic and has negligible absorption into the bloodstream, there is no expected interaction with oral vitamins or dietary supplements.


Q: Can Cicaderm make my skin more sensitive to sunlight?

Official regulatory guidance indicates that it does not. Zinc Oxide, the active ingredient, is an inorganic compound that is not generally associated with causing photosensitivity or increasing sensitivity to sunlight.


Q: Are there different strengths of Cicaderm available?

Yes. According to official product listings, topical protectants containing Zinc Oxide are commonly available in several different concentrations. These strengths generally range between 10% and 40%.


Q: Is Cicaderm appropriate for use on the face?

The product is approved for use as a topical protectant on the skin. The primary regulatory warning is to avoid contact with the eyes; no other restrictions on general facial application sites are explicitly listed.


Q: Does using Cicaderm require special monitoring?

Official product documentation indicates that no specific laboratory tests or clinical monitoring are required for this product. This is consistent with its classification as a non-systemic product that is not intended for absorption.


Q: Is there a risk of developing a resistance to Cicaderm over time?

Official information indicates that there is no expected risk of developing resistance. The primary mechanism of action is mechanical, relying on the physical formation of a protective barrier on the skin's surface.

How should Cicaderm be stored and disposed of?

How to Store and Dispose of Cicaderm

Official regulatory documents define strict storage and disposal requirements to maintain the product's quality and ensure public safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F).
Protection Keep the product in its original, tightly closed container to protect it from excessive moisture and light.
Handling Do not freeze the product, as this can compromise the formulation. If reconstituted, follow specific in-use stability rules for the duration and temperature.
Safety Keep Cicaderm strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Cicaderm must not be disposed of in household trash or flushed down a toilet or drain. Utilize an authorized pharmaceutical take-back program or follow local waste collection guidelines for medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cicaderm found in:

A-Z Index: